# Lars Rydén

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lars-ryden-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,363 |
| Field | Diabetes Treatment and Management |
| h-index | 59 |
| i10-index | 162 |
| Last Known Institution | Karolinska University Hospital |
| OpenAlex ID | https://openalex.org/A5041670111 |
| ORCID iD | https://orcid.org/0000-0002-5430-4697 |
| Works | 250 |

## Researcher papers

- [Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind-a-double-blind/)
- [ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD](https://scholariq.org/papers/esc-guidelines-on-diabetes-pre-diabetes-and-cardiovascular-diseases-developed-in/)
- [Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year](https://scholariq.org/papers/randomized-trial-of-insulin-glucose-infusion-followed-by-subcutaneous-insulin/)
- [Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity](https://scholariq.org/papers/intense-metabolic-control-by-means-of-insulin-in-patients-with-diabetes-mellitus/)
- [EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries](https://scholariq.org/papers/euroaspire-iv-a-european-society-of-cardiology-survey-on-the-lifestyle-risk/)
- [Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries](https://scholariq.org/papers/management-of-dyslipidaemia-in-patients-with-coronary-heart-disease-results-from/)
- [Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials](https://scholariq.org/papers/benefits-and-harms-of-drug-treatment-for-type-2-diabetes-systematic-review-and/)
- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [Design and baseline characteristics of participants in the <scp>R</scp> esearching cardiovascular <scp>E</scp> vents with a <scp>W</scp> eekly <scp>IN</scp> cretin in <scp>D</scp> iabetes ( <scp>REWIND</scp> ) trial on the cardiovascular effects of dulaglutide](https://scholariq.org/papers/design-and-baseline-characteristics-of-participants-in-the-scp-r-scp-esearching/)
- [The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial](https://scholariq.org/papers/the-effect-of-dulaglutide-on-stroke-an-exploratory-analysis-of-the-rewind-trial/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)

## Researcher university

- [Karolinska University Hospital](https://scholariq.org/institutions/karolinska-university-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.